A recent lecture has outlined the many new opportunities for small biotechs to develop lasting and valuable partnerships with Japanese pharmaceutical companies
Stuart McGuire, senior business development executive at mid-sized CRO Chiltern International, spoke at the 3rd BioIndustry Association (BIA) regional workshop on the globalisation prospects for small biotech companies.
During his lecture, he focused on the variety of opportunities for British firms to collaborate with Japanese pharmaceutical companies, particularly in the area of later phase clinical research. "The plain fact is that Japanese companies are carrying out significantly more late phase clinical trial work in Europe than ever before," he explained.
"For biotech companies with the right type of strategies and a willingness to collaborate, there are some very exciting opportunities on offer." McGuire also highlighted the increasing importance to Japanese pharmaceutical companies of the European market and their collaborations with contract research organisations (CRO) to improve drug development in different countries.
"As the pharmaceutical industry operates on an international basis, European partners who understand how regulations and clinical practices vary between countries are an invaluable asset in getting a drug successfully to market," he added.
